Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89.
View in:
PubMed
subject areas
Androgen Receptor Antagonists
Animals
Antineoplastic Combined Chemotherapy Protocols
Benzamides
Benzoates
Bridged Bicyclo Compounds, Heterocyclic
Cell Line, Tumor
Cell Survival
Dexamethasone
Drug Resistance, Neoplasm
HEK293 Cells
Humans
Immediate-Early Proteins
Immunoblotting
Male
Metribolone
Mice
Mice, Nude
Microscopy, Fluorescence
Mifepristone
Nitriles
Phenylthiohydantoin
Prostatic Neoplasms
Receptors, Androgen
Receptors, Glucocorticoid
Reverse Transcriptase Polymerase Chain Reaction
RNA Interference
Xenograft Model Antitumor Assays
authors with profiles
Suzanne D. Conzen
Russell Z. Szmulewitz